Creating advanced CAR T cells from stem cells for better cancer treatment
Engineering detours around the biologic barriers to allogeneic, iPSC-derived CAR T immunotherapy
['FUNDING_FELLOWSHIP'] · UNIVERSITY OF CALIFORNIA LOS ANGELES · NIH-10854727
This study is working on making CAR T cell therapy better for people with certain blood cancers by using special stem cells that can be modified to work more effectively, aiming to create a safer and more reliable treatment for patients.
Quick facts
| Phase | ['FUNDING_FELLOWSHIP'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UNIVERSITY OF CALIFORNIA LOS ANGELES (nih funded) |
| Locations | 1 site (LOS ANGELES, UNITED STATES) |
| Trial ID | NIH-10854727 on ClinicalTrials.gov |
What this research studies
This research focuses on improving CAR T cell therapy, which has shown promise in treating certain blood cancers. The team aims to develop CAR T cells from allogeneic human pluripotent stem cells, which can be genetically modified to enhance their effectiveness. By addressing biological barriers that hinder the production of these cells, the researchers hope to create a more consistent and effective treatment option for patients. The approach includes innovative techniques to ensure the T cells develop properly and do not trigger adverse reactions in patients.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients with hematological malignancies who may benefit from CAR T cell therapy.
Not a fit: Patients with solid tumors or those who do not have hematological malignancies may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more reliable and effective CAR T cell therapies for patients with difficult-to-treat cancers.
How similar studies have performed: Previous research has shown promise in using stem cells for CAR T cell therapy, but this specific approach is innovative and not widely tested.
Where this research is happening
LOS ANGELES, UNITED STATES
- UNIVERSITY OF CALIFORNIA LOS ANGELES — LOS ANGELES, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: YOO, SANG PIL — UNIVERSITY OF CALIFORNIA LOS ANGELES
- Study coordinator: YOO, SANG PIL
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.